Celltrion셀트리온
068270 · KOSPI · ₩CELLTRION · 셀트리온
₩188,600▼ ₩1,400 (0.74%)End-of-day · Oct 27, 2026 · End-of-day prices.
Filings
- Amended: Preliminary earnings (consolidated)[기재정정]연결재무제표기준영업(잠정)실적(공정공시)Oct 27, 2026Open on DART
Predicted impact: Low
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 27, 2026Open on DART
Predicted impact: Low
- Share buyback decision주요사항보고서(자기주식취득결정)Oct 26, 2026Open on DART
Predicted impact: Low
Share buyback decision; size not given, so treated as routine until amount is disclosed.
- Major management matter relevant to investors투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결)Oct 22, 2026Open on DART
Predicted impact: Low
License-in of long-acting anti-APRIL antibody; deal up to ₩769.5B already reported, small vs market value.
- Report on Treasury Stock Acquisition Results자기주식취득결과보고서Oct 20, 2026Open on DART
Predicted impact: Low
Report on completed buyback results; size not given and the buyback was likely already known.
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인)Oct 14, 2026Open on DART
Predicted impact: Low· Actual: +1.0% vs sector, volume 2.1× normal (5 trading days)
Phase 3 trial approval for a product is meaningful but small versus revenue, and US PBM listing news was already reported.
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Oct 12, 2026Open on DART
Predicted impact: Medium· Actual: +3.0% vs sector, volume 1.9× normal (5 trading days)
Preliminary consolidated results for a very large company; gap to last year unknown.
- Share buyback decision주요사항보고서(자기주식취득결정)Sep 29, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인)Sep 23, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Sep 23, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2))Sep 21, 2026Open on DART
- Share cancellation decision주식소각결정Sep 16, 2026Open on DART
- Report on Treasury Stock Acquisition Results자기주식취득결과보고서Sep 16, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인)Sep 7, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)Sep 7, 2026Open on DART
- Matters Related to Timely Disclosure Obligations (Fair Disclosure)수시공시의무관련사항(공정공시)Aug 31, 2026Open on DART
- Share buyback decision주요사항보고서(자기주식취득결정)Aug 31, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Aug 28, 2026Open on DART
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Aug 28, 2026Open on DART
- Response to rumour or news report풍문또는보도에대한해명(미확정)Aug 25, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품목허가 신청)Aug 24, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 21, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Aug 14, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청)Aug 3, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Aug 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 미국 품목허가 신청)Jul 30, 2026Open on DART
- Amended: Preliminary earnings (consolidated)[기재정정]연결재무제표기준영업(잠정)실적(공정공시)Jul 27, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 신청(류마티스 관절염 환자))Jul 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 신청 (류마티스 관절염 환자))Jul 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 신청(Part1&2) (류마티스 관절염 환자))Jul 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 유럽 품목허가 신청)Jul 24, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 24, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jul 16, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 유럽 임상 3상 조기종료 및 시험계획 자진취하)Jul 14, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청(Part1&2))Jul 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 7, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청)Jul 6, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Jul 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
Titles in Korean until English translations are added.
Also known as: Celltrion / 셀트리온 / 068270 / KRX:068270
Source: KRX statistical information